Leukemia Research
Volume 30, Issue 4 , Pages 415-426 , April 2006

A Fas agonist induces high levels of apoptosis in haematological malignancies

  • Peter Greaney

      Affiliations

    • Apoxis S.A., 18–20 Avenue de Sévelin, 1004 Lausanne, Switzerland
    • These authors contributed equally to the work.
    • ,
  • Aimable Nahimana

      Affiliations

    • Service of Hematology, University Hospital of Lausanne (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland
    • These authors contributed equally to the work.
    • ,
  • Lucienne Lagopoulos

      Affiliations

    • Service of Hematology, University Hospital of Lausanne (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland
    • ,
  • Anne-Lise Etter

      Affiliations

    • Apoxis S.A., 18–20 Avenue de Sévelin, 1004 Lausanne, Switzerland
    • ,
  • Dominique Aubry

      Affiliations

    • Service of Hematology, University Hospital of Lausanne (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland
    • ,
  • Antoine Attinger

      Affiliations

    • Apoxis S.A., 18–20 Avenue de Sévelin, 1004 Lausanne, Switzerland
    • ,
  • Nicola Beltraminelli

      Affiliations

    • Apoxis S.A., 18–20 Avenue de Sévelin, 1004 Lausanne, Switzerland
    • ,
  • Boris Huni

      Affiliations

    • Apoxis S.A., 18–20 Avenue de Sévelin, 1004 Lausanne, Switzerland
    • ,
  • Isabelle Bassi

      Affiliations

    • Apoxis S.A., 18–20 Avenue de Sévelin, 1004 Lausanne, Switzerland
    • ,
  • Bernard Sordat

      Affiliations

    • Apoxis S.A., 18–20 Avenue de Sévelin, 1004 Lausanne, Switzerland
    • ,
  • Stéphane Demotz

      Affiliations

    • Apoxis S.A., 18–20 Avenue de Sévelin, 1004 Lausanne, Switzerland
    • ,
  • Marc Dupuis

      Affiliations

    • Apoxis S.A., 18–20 Avenue de Sévelin, 1004 Lausanne, Switzerland
    • ,
  • Michel A. Duchosal

      Affiliations

    • Service of Hematology, University Hospital of Lausanne (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland
    • Corresponding Author InformationCorresponding author. Tel.: +41 21 31 44215.

Received 13 May 2005 ,Accepted 8 August 2005.

References 

  1. El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signalling. Cell Death Differ. 2001;8(11):1066–1075
  2. Cullen KV, Davey RA, Davey MW. Drug resistance does not correlate with resistance to Fas-mediated apoptosis. Leuk Res. 2001;25(1):69–75
  3. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res. 2000;256:58–66
  4. Takayama H, Kojima H, Shinohara N. Cytotoxic T lymphocytes: the newly identified Fas (CD95)-mediated killing mechanism and a novel aspect of their biological functions. Adv Immunol. 1995;60:289–321
  5. Krammer PH. CD95(APO-1/Fas)-mediated apoptosis: live and let die. Adv Immunol. 1999;71:163–210
  6. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol. 2003;23(4):1428–1440
  7. Timmer T, de Vries EG, de Jong S. Fas receptor-mediated apoptosis: a clinical application?. J Pathol. 2002;196(2):125–134
  8. Westendorf JJ, Lammert JM, Jelinek DF. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood. 1995;85(12):3566–3576
  9. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood. 1995;85(3):757–764
  10. Li Q, Tsuruda K, Sugahara K, Dateki N, Ohishi E, Yamada Y, et al. Qualitative and quantitative characterization of Fas (CD95) expression and its role in primary human acute leukemia cells. Leuk Res. 2000;24(5):437–444
  11. Min YH, Lee S, Lee JW, Chong SY, Hahn JS, Ko YW. Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy. Br J Haematol. 1996;93(4):928–930
  12. Iijima N, Miyamura K, Itou T, Tanimoto M, Sobue R, Saito H. Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy. Blood. 1997;90(12):4901–4909
  13. Dutton A, O’Neil JD, Milner AE, Reynolds GM, Starczynski J, Crocker J, et al. Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc Natl Acad Sci USA. 2004;101(17):6611–6616
  14. Tepper CG, Seldin MF. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Blood. 1999;94(5):1727–1737
  15. Gutierrez MI, Cherney B, Hussain A, Mostowski H, Tosato G, Magrath I, et al. Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis. Cancer Res. 1999;59(3):696–703
  16. Juo P, Kuo CJ, Yuan J, Blenis J. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol. 1998;8(18):1001–1008
  17. Tsao TS, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol. 2002;440(2–3):213–221
  18. Dick JE, Bhatia M, Gan O, Kapp U, Wang JC. Assay of human stem cells by repopulation of NOD/SCID mice. Stem Cells. 1997;15(Suppl. 1):199–203(discussion 204–7)
  19. Rozenfeld-Granot G, Toren A, Amariglio N, Brok-Simoni F, Rechavi G. Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies. Exp Hematol. 2001;29(2):228–233
  20. Panayiotidis P, Ganeshaguru K, Foroni L, Hoffbrand AV. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia. 1995;9(7):1227–1232
  21. Kamihira S, Yamada Y, Hirakata Y, Tsuruda K, Sugahara K, Tomonaga M, et al. Quantitative characterization and potential function of membrane Fas/APO-1 (CD95) receptors on leukaemic cells from chronic B and T lymphoid leukaemias. Br J Haematol. 1997;99(4):858–865
  22. Wang D, Freeman GJ, Levine H, Ritz J, Robertson MJ. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol. 1997;97(2):409–417
  23. Kim K, Fisher MJ, Xu SQ, el-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res. 2000;6(2):335–346
  24. Tsuruda K, Yamada Y, Hirakata Y, Sugahara K, Maeda T, Atogami S, et al. Qualitative and quantitative characterization of Fas (APO-1/CD95) on leukemic cells derived from patients with B-cell neoplasms. Leuk Res. 1999;23(2):159–166
  25. Meinhardt G, Wendtner CM, Hallek M. Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. J Mol Med. 1999;77(2):282–293
  26. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest. 2005;115(2):369–378
  27. Roue G, Lancry L, Duquesne F, Salaun V, Troussard X, Sola B. Upstream mediators of the Fas apoptotic transduction pathway are defective in B-chronic lymphocytic leukemia. Leuk Res. 2001;25(11):967–980
  28. MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene. 2002;21(44):6809–6818
  29. Kim DK, Cho ES, Yoo JH, Um HD. FLIP is constitutively hyperexpressed in Fas-resistant U266 myeloma cells, but is not induced by IL-6 in Fas-sensitive RPM18226 cells. Mol Cells. 2000;10(5):552–556
  30. Dive C, Evans CA, Whetton AD. Induction of apoptosis—new targets for cancer chemotherapy. Semin Cancer Biol. 1992;3(6):417–427
  31. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood. 1997;89(6):1845–1853
  32. Matsubara K, Kubota M, Adachi S, Kuwakado K, Hirota H, Wakazono Y, et al. Induction of apoptosis in childhood acute leukemia by chemotherapeutic agents: failure to detect evidence of apoptosis in vivo. Eur J Haematol. 1994;52(1):47–52
  33. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene. 2004;23:2950–2966
  34. Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood. 1999;93(6):1992–2002
  35. van Kooten C, Banchereau J. CD40–CD40 ligand. J Leukoc Biol. 2000;67(1):2–17
  36. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40–ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96(9):2917–2924
  37. Romano C, De Fanis U, Sellitto A, Dalla Mora L, Chiurazzi F, Giunta R, et al. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2003;44(11):1963–1971
  38. Romano C, Fanis UD, Sellitto A, Chiurazzi F, Guastafierro S, Giunta R, et al. Induction of CD95 upregulation does not render chronic lymphocytic leukemia B-cells susceptible to CD95-mediated apoptosis. Immunol Lett. 2005;97(1):131–139
  39. de Vries EG, Timmer T, Mulder NH, van Geelen CM, van der Graaf WT, Spierings DC, et al. Modulation of death receptor pathways in oncology. Drugs Today (Barc). 2003;39(Suppl. C):95–109
  40. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 1989;245(4915):301–305
  41. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364(6440):806–809
  42. van Besien K, Loberiza FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102(10):3521–3529
  43. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J, Anderson WF, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993;341(8837):85–86
  44. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 1994;83(10):3068–3076
  45. Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, Litzow MR. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant. 1997;19(4):337–342
  46. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495–2502
  47. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89(3):789–793
  48. Kim H, Whartenby KA, Georgantas RW, Wingard J, Civin CI. Human CD34+ hematopoietic stem/progenitor cells express high levels of FLIP and are resistant to Fas-mediated apoptosis. Stem Cells. 2002;20(2):174–182

PII: S0145-2126(05)00314-0

doi: 10.1016/j.leukres.2005.08.006

Leukemia Research
Volume 30, Issue 4 , Pages 415-426 , April 2006

Article Tools

* Image Usage & Resolution